Welcome to our dedicated page for Intercure Ltd. SEC filings (Ticker: INCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InterCure Ltd. filings document foreign private issuer reports for a medical cannabis company operating as Canndoc. Form 6-K disclosures furnish press releases, interim financial statements, management discussion and XBRL data covering revenue, Adjusted EBITDA, cash flow, cash balances, and production, importation and sales from the company's cannabis operations.
The filing record also covers Nasdaq minimum bid compliance for InterCure's ordinary shares, annual general meeting proxy materials, governance matters, material agreements related to cannabis science and pharmaceutical innovation, and risk disclosures tied to service providers, court proceedings, outstanding checks and operating continuity.
InterCure Ltd. reported that it received a Nasdaq notice on February 25, 2026 stating that its ordinary shares failed to meet the minimum bid requirement, having closed below $1.00 for 30 consecutive business days. Under Nasdaq rules, InterCure has until August 24, 2026 to regain compliance by maintaining a closing bid price at or above $1.00 for at least 10 consecutive business days.
The company expects it could qualify for an additional 180‑day grace period if it meets other Nasdaq Capital Market standards and applies to transfer. InterCure is monitoring its share price and is considering a reverse share split, subject to corporate and regulatory approvals, as part of its plan. Its shares will continue trading on the Nasdaq Global Market while it works to restore compliance.
InterCure Ltd. announced preliminary 2025 results showing estimated revenue of NIS 265 million, about 11% higher than 2024, and positive Adjusted EBITDA. This marks the company’s twelfth consecutive half-year with positive Adjusted EBITDA and demonstrates continued profitability in its cannabis operations.
Revenue in the second half of 2025 was nearly 20% above the same period a year earlier, supported by the company’s first significant revenues from the German market. InterCure reported cash of NIS 43 million, including restricted cash and deposits, and plans to publish full audited 2025 results in an annual report by the end of April 2026.
InterCure Ltd. (dba Canndoc) reported a potential credit and operational issue related to its service provider Bazelet. The company learned that the Bazelet group of companies, a leading producer of cannabis oil and a key provider of production, EU-GMP-certified export, and Israeli distribution services, has entered restructuring proceedings in an Israeli District Court, including a temporary stay of proceedings.
InterCure holds Bazelet-issued checks totaling approximately NIS 27 million that remain outstanding during this stay, creating exposure to possible non-payment. The company states it is monitoring court developments, intends to pursue legal actions to protect its rights and interests as directed by its board, and is evaluating collaboration with an additional packaging facility to secure alternative service capacity.
InterCure Ltd. reported that it will hold its Annual General Meeting of Shareholders on December 30, 2025 at 4:00 p.m. (Israel time) at the offices of its legal counsel in Tel Aviv, Israel. The company is providing shareholders with a Notice and Proxy Statement describing the proposals to be voted on and the procedures for voting in person or by proxy, together with a Proxy Card that enables holders of ordinary shares to vote without attending the meeting. These materials are furnished as exhibits to the report so shareholders can review the agenda and participate in the decision-making process for the company.
InterCure Ltd. furnished a Form 6-K announcing it issued a press release on November 3, 2025 titled “InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation.” The press release is attached as Exhibit 99.1.
The filing highlights a strategic investment and collaboration framework with Cannasoul, focused on advancing cannabis science and pharmaceutical innovation. Additional details are contained in the attached press release.
InterCure Ltd. furnished a Form 6-K that packages its first-half 2025 financial disclosure materials, including a press release, interim financial statements, and management’s discussion and analysis. The press release headline states that InterCure generated NIS 130 million in revenue in the first half of 2025 and reported positive operating cash flow, indicating that its core operations brought in more cash than they consumed over that period.
The accompanying exhibits include condensed consolidated unaudited interim financial statements and a detailed analysis of financial condition and results of operations as of and for the six months ended June 30, 2025, along with related XBRL data files.
InterCure Ltd. is entering a two-phase acquisition of Israeli cannabis technology and brand company ISHI (Botanico Ltd.) through a share purchase agreement. InterCure will first acquire 50% of ISHI’s fully diluted share capital in exchange for 2,261,345 ordinary shares and 205,710 options, then acquire the remaining 50% for an additional 2,252,317 shares and 204,889 options once ISHI posts three consecutive months of positive operating profitability or after 24 months. The total consideration of 4,513,663 shares and 410,599 options represents about 10% of InterCure’s fully diluted shares immediately before the initial closing. ISHI security holders face Rule 144 restrictions and an extra lock-up limiting sales to up to 33% of InterCure’s prior-day Nasdaq trading volume, and two ISHI founders will join InterCure’s leadership team. The initial closing is expected in the first quarter of 2026, subject to Israeli regulatory approvals, with all securities issued in a private placement exempt from U.S. registration.